Sumitomo Pharma Co., Ltd. revised consolidated earnings guidance for the fiscal year ending March 31, 2023. For the year, the company now expects revenue to be JPY 604,000 million, operating loss to be JPY 30,000 million, net loss attributable to owners of the parent to be JPY 15,000 million and basic loss per share to be JPY 37.76 against revenue of JPY 550,000 million, operating profit of JPY 24,000 million, net profit attributable to owners of the parent of JPY 22,000 million and basic earnings per share of JPY 55.37 as previously forecasted.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
410 JPY | +2.50% | +5.40% | -12.02% |
Apr. 22 | Lull in Geopolitical Tensions Lifts Asian Stock Markets | MT |
Apr. 17 | Jefferies Adjusts Sumitomo Pharma’s Price Target to 420 Yen From 520 Yen, Keeps at Hold | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.02% | 1.02B | |
+25.83% | 653B | |
+27.00% | 556B | |
-6.76% | 354B | |
+20.34% | 331B | |
+3.00% | 296B | |
+13.09% | 233B | |
+5.46% | 201B | |
-9.61% | 193B | |
-6.26% | 144B |
- Stock Market
- Equities
- 4506 Stock
- News Sumitomo Pharma Co., Ltd.
- Sumitomo Pharma Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023